Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERY974 with Atezolizumab and Bevacizumab in Advanced HCC
NCT05022927Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of ERY974 in hepatocellular carcinoma (HCC) (5 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicities at Cycle 2, Electrocardiograms up to 52 weeks and 4 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
ERY974
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05022927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022927.